Akiko Sarashina

Akiko Sarashina

UNVERIFIED PROFILE

Are you Akiko Sarashina?   Register this Author

Register author
Akiko Sarashina

Akiko Sarashina

Publications by authors named "Akiko Sarashina"

Are you Akiko Sarashina?   Register this Author

20Publications

466Reads

18Profile Views

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2015 Dec 11;76(6):1225-33. Epub 2015 Nov 11.

Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2896-3DOI Listing
December 2015

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Cancer Chemother Pharmacol 2015 Oct 8;76(4):739-50. Epub 2015 Aug 8.

Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2826-4DOI Listing
October 2015

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

J Thorac Oncol 2015 Feb;10(2):346-52

*Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan; †Center for Clinical and Translational Research, Faculty of Medicine, Kyusyu University Hospital, Fukuoka, Japan; ‡Department of Internal Medicine, Suita Municipal Hospital, Osaka, Japan; §Department of Medical Oncology, Nara Hospital, Kinki University Faculty of Medicine, Nara, Japan; ║Department of Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Fukuoka, Japan; ¶Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka, Japan; #Department of Thoracic Oncology, Kansai Medical University, Hirakata Hospital, Osaka, Japan; **Department of Medical Oncology, National Kyushu Cancer Centre, Fukuoka, Japan; ††Department of Medical Oncology, National Kyushu Cancer Centre, Fukuoka, Japan; ‡‡Nippon Boehringer Ingelheim Co. Ltd., Medical Development Division, Hyogo, Japan; and §§Clinical Pharmacokinetics/Pharmacodynamics Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000395DOI Listing
February 2015

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.

Drug Metab Pharmacokinet 2013 13;28(3):213-9. Epub 2012 Nov 13.

Clinical PK/PD Group, Medical Development Division, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.dmpk-12-rg-082DOI Listing
January 2014

Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients.

Drug Metab Pharmacokinet 2003 ;18(3):203-11

Department of Drug Metabolism and Pharmacokinetics, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.18.203DOI Listing
March 2005

Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

Drug Metab Pharmacokinet 2004 Feb;19(1):15-23

Department of Drug Metabolism and Pharmacokinetics, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., Kawanishi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.19.15DOI Listing
February 2004

Relationship between pharmacokinetic parameters and occurrence of adverse events in clinical trials performed in Europe and United States for an angiotensin II receptor antagonist, telmisartan.

Drug Metab Pharmacokinet 2004 Feb;19(1):24-32

Department of Drug Metabolism and Pharmacokinetics, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., Kawanishi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.19.24DOI Listing
February 2004